MS is a progressive, neurological condition of the brain and spinal cord (central nervous system) and symptoms or attacks include impaired mobility and vision, severe fatigue and cognitive difficulties.
There is no known cause or cure for the condition and approximately three times as many women than men are diagnosed with MS.
Bridging the gap between early diagnosis and therapeutic treatment in neurological diseases through intelligent, connected, proactive and evidence-based technological interventions is the goal of the new European project, called ALAMEDA and AISM with its Foundation is a partner.
Alameda translated as a tree-shaded promenade and
About ALAMEDA
ALAMEDA intends to research and propose a new generation of personalised artificial intelligence health support systems for people with neurological diseases and disorders, such as Parkinson’s, Multiple Sclerosis ( SM ) and Stroke (PMMS: Parkinson’s, Multiple Sclerosis and Stroke).
These applications will provide doctors with the opportunity to modify interventions based on personalised data records, which could include both pharmacological and non-pharmacological therapeutic options, such as rehabilitation.
ALAMEDA‘s machine learning and artificial intelligence methodology will ensure that algorithms are interpretable and provide explanations for their outcomes.
Digital transformation is increasingly a priority and a necessity due to the global shortage of healthcare professionals, which is believed to reach a deficit of around 4.1 million qualified healthcare professionals (midwives, nurses and doctors ) by 2030 in the EU, according to the World Health Organization.
That’s why the design and development of innovative tools has opened up new opportunities to improve healthcare and personalised care.
In the case of research on neurological diseases, for example, the methods of Big Data Analytical and Machine Learning can provide important and meaningful information, also as predictive tools.
Neurological disorders are in third place in terms of years of life lost due to health problems, disabilities or early death after cancer and cardiovascular disease.
At the basis of the ALAMEDA project there an awareness that the treatment of patients with neurological disorders is complex and that the manifestations of some diseases could worsen over time and seriously compromise the quality the life of patients and their caregivers: regular assessments of rehabilitation treatment will be essential to ensure that medical interventions have an impact and that spill-over episodes can be expected.
Although we have seen a continuous increase in knowledge and a better understanding of the value of specific measures and treatment programs, an adequate assessment of the impact of rehabilitation on patients with PMSS remains an urgent challenge to be faced to increase the ability of the health system to make it possible to develop new and personalised treatment options.
The ALAMEDA Consortium brings together technical experts, doctors and patient associations to rethink and revolutionise the ways in which patients are treated with PMSS, with the ultimate goal of improving their quality of life.
Dr. Konstantinos Demestichas, ALAMEDA coordinator and head of the research and development project at the Institute of Communication and Computer Systems, Greece.
In the healthcare sector, Deep Learning is expected to lead to a breakdown, paving the way for a paradigm shift in clinical decision support systems (CDSS Clinical Decision Support Systems), in the diagnosis and selection of treatment.
This change is further fuelled by recent advances in the digitisation of medical records, including resources such as medical reports, images or sensory data.
As a partner of the European Alameda project, AISM and its Foundation continue their efforts to provide people with MS with personalised therapies through intelligent technological interventions, of which this pandemic has underlined the importance.
Alameda translated as a tree-shaded promenade and
European Project MULTI-ACT
There are several projects and networks in which the Association who play a fundamental role: starting from European project MULTI ACT to the Multiple Sclerosis International Federation ( MSIF ) and the European MS Platform, to the Progressive MS Alliance and PROMS.
In this project, AISM aims to contribute with a pilot clinical study that has the ambition to predict the course of Multiple Sclerosis starting from the person’s perspective.
The Association firmly believes that each of them has the right to a good quality of life and full social integration.
Recent Comments